Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Placental MicroRNAs Diagnosis Pregnancy Progress and Fetal Distress

By LabMedica International staff writers
Posted on 28 Sep 2021
Analysis of placental microRNAs (miRNAs), which also circulate in the maternal blood, represents a significant improvement to currently used pregnancy screening tools, allowing assessment of placental health, and therefore fetal health, in real time.

The critical role of the placenta in successful pregnancy is clear, and there is also evidence linking developmental programming of chronic adult disease such as heart disease, diabetes, and obesity with the placental phenotype in utero. More...
However, there are currently no non-invasive tests to determine which women are likely to develop pregnancy complications in routine use, nor is there a comprehensive reference set of miRNA expression during early pregnancy that can be used for development of pregnancy health biomarkers.

MiRNAs comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.

Investigators at Flinders University (Adelaide, Australia) generated miRNA profiles using 96 placentas from presumed normal pregnancies, across early gestation, in combination with matched profiles from maternal plasma. Placenta samples ranged from six to 23 weeks’ gestation, a time period that included placenta from the early, relatively low but physiological (six to10 weeks’ gestation) oxygen environment, and later, physiologically normal oxygen environment (11 to 23 weeks’ gestation).

The results identified 637 miRNAs with expression in 86 samples. Of these, 374 were differentially expressed (DE) miRNAs between placentas from six to10 weeks’ versus 11 to 23 weeks’ gestation. Proportional change in expression of placenta-specific miRNA clusters was reflected in maternal plasma. In particular, the amount of a cluster of miRNAs from Chromosome 19, which are only made by the placenta and are present in maternal blood, changed in response to the initiation of maternal blood flow into the placenta after 10 weeks of gestation.

"Our group has had a long-term interest in developing screening tests to identify pregnant women early in pregnancy who are at risk of pregnancy complications," said senior author Dr. Claire Roberts, professor of medicine and public health at Flinders University. "The earlier we can identify those at risk the earlier we can implement extra clinical monitoring and prevention strategies."

The placenta miRNA study was published in the August 19, 2021, online edition of the journal RNA Biology.

Related Links:
Flinders University


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.